# Amiodarone-Infused CardiaMend Patches for the Prevention of New-Onset POAF in Cardiac Surgery Subjects

> **NCT06730828** · PHASE1,PHASE2 · RECRUITING · sponsor: **Helios Cardio Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Atrial Fibrillation, Postoperative

## Interventions

- **COMBINATION_PRODUCT:** The intervention includes Amiodarone-Infused CardiaMend patches (70mg, 150mg and 300mg)

## Key facts

- **NCT ID:** NCT06730828
- **Lead sponsor:** Helios Cardio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-16
- **Primary completion:** 2025-11
- **Final completion:** 2026-05
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06730828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06730828, "Amiodarone-Infused CardiaMend Patches for the Prevention of New-Onset POAF in Cardiac Surgery Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06730828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*